An unsupervised remote cognitive assessment predicts mild cognitive impairment and associates to amyloid status

Abstract

Background: The use of digital biomarkers to assess cognition in Alzheimer’s disease (AD) offers scalable, efficient alternatives to paper‐and‐pencil tests. Validating these tools against clinical and biomarker‐defined groups is critical for their adoption in research, clinical trials and clinical contexts.